Will SGLT2 combi benefit expansion eventually not happen?

11 companies' voluntary cut rate seems to fall short of expectations

Discussions on the expansion of the combination will be closed

There is a possibility of further consultation on ways to reduce the weak price

#iDiscussions on the expansion of combined benefits between SGLT-2 drugs and other drugs continue to conflict.

 

The government presented a voluntary cut rate to related companies last month to analyze their fiscal impact based on it, which is known to fall short of expectations.

 

As a result, it is expected that it will soon be decided whether to continue the discussion or end it.

 

According to the industry on the 11th, the results of the analysis of the financial impact of the voluntary reduction rate of the upper limit of drugs submitted by 11 diabetes companies to the Ministry of Health and Welfare last month fell short of expectations.

 

The drugs currently under discussion for salary expansion are three-drug therapy such as metformin+SGLT-2+DPP-4, metformin+SGLT-2+TZD, and SGLT-2 +Sulfonylurea or insulin combination therapy.

 

These combination treatments are effective in treating diabetes, so they have continuously demanded pay expansion, focusing on related academic societies.

 

The Ministry of Health and Welfare planned to receive voluntary cuts from companies with these drugs and analyze the financial impact and skip drug price negotiations with the Drug Benefit Evaluation Committee if it meets the expected range and reflect them in the salary through a report by the Health Insurance Policy Review Committee.

 

Otherwise, if the financial increase reflecting the weak cut is greater than expected, it has been delivered to companies through a meeting that it will end discussions on the expansion of combined use.

 

An industry official said, "The voluntary cut rate submitted by companies does not seem to be at the level that the Ministry of Health and Welfare thinks," adding, "If the voluntary cut rate falls below expectations, it is highly likely to end the discussion as announced at the meeting." Since this discussion has been going on for a long time since 2016 through the Diabetes Association, the government will feel burdened to end it immediately.

 

Some analysts say that there is a possibility of receiving another voluntary cut rate.

 

Another official from the pharmaceutical industry said, "So far, we have not notified the company of the results of the financial impact analysis, but I don't think the ait is good," adding, "I think we will discuss ways to cut the weak price once again."